Trial
NCT02688764
A Study to Investigate the Safety and Efficacy of PA21 (Velphoro®) and Calcium Acetate (Phoslyra®) in Paediatric and Adolescent Chronic Kidney Disease (CKD) Patients With Hyperphosphataemia
Phase IIITERMINATEDREGULATORYConfidence: HIGH
Sponsor
Vifor Fresenius Medical Care Renal Pharma
Collaborators
—
Condition
Hyperphosphatemia
Intervention
PA21 (Velphoro®)
Why stopped
The study was prematurely ended due to the modification of study requirements by the US Food and Drug Administration and the European Medicines Agency
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-09-10